Biodesix partner, Friends of Cancer Research, publishes data in clinical cancer research showing a strong association between CTDNA alterations and treatment outcomes for patients with solid tumor types

Biodesix partner, Friends of Cancer Research, publishes data in clinical cancer research showing a strong association between CTDNA alterations and treatment outcomes for patients with solid tumor types

Biodesix, Inc, a leading diagnostic solutions company, and Bio-Rad Laboratories, a global leader in life sciences research and diagnostics, contributed new research from Friends of Cancer Research's (Friends') CTMonitr project, recently published in Clinical Cancer Research (CCR) was published. The results demonstrate a strong association between changes in circulating tumor DNA (CTDNA) and treatment outcomes, providing the potential for integrating CTDNA analysis into therapeutic development programs and clinical cancer care.

The CTMonitr (CTDNA for Treatment Delivery Monitoring) project was designed to determine whether changes in patient CTDNA levels predict treatment outcomes. Results from the first phase of the project showed a strong association between changes in CTDNA and overall survival in patients with ANSCLC treated with immune checkpoint inhibitors (published in the Journal of Clinical Oncology). The new data from CTMonitr's second phase expands the analysis to additional solid tumor types and treatment categories, including patients treated with tyrosine kinase inhibitors.

The friend-led collaborators included Biodesix along with organizations from industry, government, academic and advocacy groups. Biodessix contributed data generated using Bio-Rad Droplet Digital™ PCR (DDPCR)* technology to detect CTDNA from patient samples.

“Biodesix is ​​proud to be a partner in this important project that supports the transformation of therapeutic development and clinical cancer care,” said Gary Pestano, Chief Development Officer at Biodesix. “The CTMonitr project is aligned with the mission and vision of Biodesix development services as we strive to challenge today's science and solutions to develop and adapt clinical decision making to improve patient care and outcomes.”

We are very pleased that digital droplet PCR (DDPCR) was selected for use within this study. These collaborations and research programs are critical as we work to establish novel methods to monitor residual molecular disease in oncology and support the advancement of scientific research and ultimately healthcare. “

Steve Kulisch, Vice President Product Management, Digital Biology Group, Bio-Rad Laboratories

Beyond this specific research project, BioDesIX offers ctDNA testing using DDPCR technology as part of its development services portfolio and also studies CTDNA in combination with proteomics to detect residual molecular disease (MRD). Recent advances in this application will be presented at the American Association for Cancer Research (AACR) Annual Meeting on April 28, 2025.

*Droplet Digital and DDPCR are trademarks of Bio-Rad Laboratories, Inc.

Sources: